Table 2.
Positive in this study
|
RNA-seq
|
PVG PCR
|
RNA-seq or PVG PCR |
|||||||
---|---|---|---|---|---|---|---|---|---|---|
EPIC positive | RNA-seq | PVG PCR | RNA-seq or PVG PCR |
Sens | Spec | Sens | Spec | Sens | Spec | |
Patients (n = 63) | ||||||||||
IAV | 0 | 0 | 0 | 0 | NA | 100% | NA | 100% | NA | NA |
IBV | 1 | 1 | 0 | 1 | 100% | 100% | 0% | 100% | 100% | 100% |
HMPV | 8 | 7 | 7 | 8 | 88% | 100% | 88% | 100% | 100% | 100% |
HRVa | 12 | 12 | 2a | 12 | 100% | 100% | 17% | 100% | 100% | 100% |
RSV | 24 | 23 | 21 | 23 | 96% | 100% | 88% | 100% | 96% | 100% |
HPIV | 3 | 2 | 1 | 2 | 67% | 98% | 33% | 98% | 67% | 98% |
ADV | 3 | 0 | 1 | 1 | 0% | 100% | 33% | 100% | 33% | 100% |
HCoV | 2 | 2 | 2 | 2 | 100% | 100% | 100% | 100% | 100% | 100% |
M. pneumoniae | 7 | 7 | ND | 7 | 100% | 98% | ND | ND | 100% | 98% |
| ||||||||||
Control subjects (n = 52) | ||||||||||
IAV | 1 | 0 | 0 | 0 | 0% | 100% | 0% | 100% | 0% | 100% |
IBV | 0 | 0 | 0 | 0 | NA | 100% | NA | 100% | NA | 100% |
HMPV | 4 | 0 | 0 | 0 | 0% | 100% | 0% | 100% | 0% | 100% |
HRVa | 38 | 34 | 5a | 34 | 89% | 96% | 13% | 100% | 89% | 96% |
RSV | 5 | 0 | 1 | 1 | 0% | 100% | 20% | 100% | 20% | 100% |
HPIV | 3 | 3 | 2 | 3 | 100% | 98% | 67% | 100% | 100% | 98% |
ADV | 5 | 0 | 3 | 3 | 0% | 100% | 60% | 100% | 60% | 100% |
HCoV | 3 | 1 | 2 | 2 | 33% | 100% | 67% | 100% | 67% | 100% |
M. pneumoniae | 0 | 0 | ND | 0 | NA | 100% | ND | ND | NA | 100% |
Abbreviations: ADV, adenovirus; EPIC, Etiology of Pneumonia in the Community; HCoV, human coronavirus; HMPV, human metapneumovirus; HPIV, human parainfluenza viruses; HRV, human rhinovirus; IAV, influenza A virus; IBV, influenza B virus; M. pneumoniae, Mycoplasma pneumoniae; ND, not done; PVG PCR, pan-viral group polymerase chain reaction; RSV, respiratory syncytial virus; Sens, sensitivity; Spec, specificity.
The Picornaviridae polymerase chain reaction targets only a subset of human rhinoviruses.